Aptevo Therapeutics Inc.
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | 120.58% | |||
| Gross Profit | -- | -120.58% | |||
| SG&A Expenses | 1.79% | 13.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.92% | 1.54% | |||
| Operating Income | 3.92% | -1.54% | |||
| Income Before Tax | 3.18% | -1.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.18% | -1.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.18% | -1.52% | |||
| EBIT | 3.92% | -1.54% | |||
| EBITDA | 3.77% | -1.71% | |||
| EPS Basic | 90.44% | 43.18% | |||
| Normalized Basic EPS | 90.44% | 43.18% | |||
| EPS Diluted | 90.44% | 43.24% | |||
| Normalized Diluted EPS | 90.44% | 43.18% | |||
| Average Basic Shares Outstanding | 912.48% | 78.68% | |||
| Average Diluted Shares Outstanding | 912.48% | 78.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||